TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06176625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Amplifier Use
Description: Patient is provided amplification device and signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
Study: NCT05251506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser lancing device or lancet for blood glucose level measurement
Description: Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser lancing device or lancet for blood glucose level measurement
Description: Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
Study: NCT06316206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Dienogest 0.03mg/2mg
Description: Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest 0.03mg/2mg at any time of the menstrual cycle
Study: NCT05218408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001 systemic and Intra cavity administration
Description: Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001 systemic and Intra cavity administration
Description: Phase 1 Lymphodepletion Days -5,-4 and -3 Cyclophosphamide 900 mg/m2, Fludarabine 30 mg/m2 and Mesna per SOC~IL 2 at 6M IU subcutaneous administration:~For IV cycle ( cycle1) rhIL2 will be administered on Days 1,3,5,8,9,11 and 15 . On days 1, 8 and 15 rhIL-2 will be administered 1 to 3 hours prior to CYNK-001 infusions For IC cycles rhIL2 will be administered 1 to 3 hours prior to each CYNK-001 IC dose.~CYNK-001 : for IV at 2.4 x10\^9 or 3.6 x10\^9 cells Days 1,8 and 15~Tumor resection will take place 7 to 14 day follow by first IC cycle ( Cycle 2) at 100 Million cells or 200 Million cells~IC cycles 3,4,5 once a week for three weeks , 28 days cycle at100 Million cells or 200 Million cells only for Phase 1 cohort 4 and Phase 2a
Study: NCT05303155

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA sequencing
Description: Fecal microbiome analysis using 16S rRNA sequencing

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA sequencing
Description: Fecal microbiome analysis using 16S rRNA sequencing
Study: NCT05154955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10XB-101 Solution for Injection
Description: One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10XB-101 Vehicle Solution for Injection
Description: This is the placebo control
Study: NCT06545994

Intervention type: OTHER
Intervention: Observation
Description: It's a observational cohort study and no interventions are performed.
Study: NCT04925492

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: An imaging method that uses radiotracers to view changes in the metabolic process.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: An imaging method that uses radiotracers to view changes in the metabolic process.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-64]-LLP2A
Description: A radioactive tracer used in PET imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu-64]-LLP2A
Description: A radioactive tracer used in PET imaging.
Study: NCT04911842

Intervention type: DEVICE
Intervention: HydroMID
Description: Hydrophilic biomaterial

Intervention type: DEVICE
Intervention: TPU
Description: Thermoplastic polyurethane
Study: NCT05058469

Intervention type: DEVICE
Intervention: Tracheotomy
Description: Tracheotomy in patients +/- antiplatelet therapy

Intervention type: DEVICE
Intervention: Tracheotomy
Description: Tracheotomy in patients +/- antiplatelet therapy

Intervention type: DEVICE
Intervention: Tracheotomy
Description: Tracheotomy in patients +/- antiplatelet therapy

Intervention type: DEVICE
Intervention: Tracheotomy
Description: Tracheotomy in patients +/- antiplatelet therapy
Study: NCT05460936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Functional Training
Description: motor learning, skill progression, and resistance training to target the balance, strength, and coordination impairments of the lower extremities. Motor learning will be based on strength and balance training using tandem walks, balance boards, and one-leg standing. Skill progression will be used to challenge the LIFT and the strength training will be achieved by performing sit-to-stand, sit-ups, stair climbs, and vertical jumps

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Resistive Exercises Stretching exercise of quadriceps , hamstring adductors and abductors.
Study: NCT05949749

Intervention type: DIAGNOSTIC_TEST
Intervention: Epitope exploration
Description: Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.

Intervention type: DIAGNOSTIC_TEST
Intervention: Epitope exploration
Description: Explore the epitope landscape of gp42-IgG of cases in comparison with that of controls.
Study: NCT06087718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maastro applicator
Description: The dose profile of the Maastro applicator is similar to the dose profile of a CXRT device. Patients will be stratified based on tumor size. The cut-off is set at the maximum diameter of the treatment surface of the Maastro applicator. The boost consists of 3 fractions with a dose equivalent to 30 Gy per fraction prescribed at the surface of the applicator. The 3 boost fractions will be delivered over a 4-week time period. Patients with a tumor size \< 2.5 cm will receive an upfront boost followed by concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days). Patients with a tumor size ≥ 2.5cm will first undergo concurrent chemoradiotherapy (25x1.8 Gy combined with capecitabine 825 mg/m2 bd on radiotherapy days) and will afterwards receive the boost.
Study: NCT06421688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: After participants underwent induction of anesthesia, Ascorbic acid (Vitamin C Injection) was administered at a dosage of 50 mg/kg, diluted to 50 ml using saline, with a total amount not exceeding 4 g; pumping was performed using a micro pump at a rate of 25 ml/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After participants underwent induction of anesthesia, 50 ml of saline was used and pumped using a micro pump at a rate of 25 ml/h.
Study: NCT06256211

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol
Description: All cases will be randomized simply by opaque closed envelop and treated with either rectal or intravenous paracetamol according to the following doses.~* Rectal dose~  * Rectal paracetamol at a dose of 25 mg/kg body weight with started and then continued at a dose of 15 mg/kg body weight every 8 hours for 3 days (ten doses in total) in neonates weighing more than 1000 gm.11~ * The patient's weight is less than 1000 gm, the initial dose was 15 mg/kg body weight, and the suspense doses are 7.5 mg/kg body weight every 8 hours for 3 days (10 doses in total).11~* Intravenous dose~  * Intravenous paracetamol dose 15 mg/kg body weight every 6 hours for 3 days (12 doses in total).12~ * After the 3-day follow up echocardiogram will be done.12 This will be the end of randomization for the purpose of the study.
Study: NCT06156306

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: The CBT-I intervention will cover sleep education, stimulus control, sleep restriction, cognitive therapy and relaxation training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I combined ACT
Description: In addition to the standard CBT-I components, mindfulness, thought diary, and other ACT components will be taught in the group.
Study: NCT05715151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CQI intervention
Description: Activity 1: Reflective sessions and problem prioritisation. Activity 2: PDSA cycles. Activity 3: Group mentoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit and Feedback
Description: Audit and Feedback on six key AA indicators, patients reported experience about access and selected AA processes.
Study: NCT05334758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Self COVID-19 Antigen Home Test
Description: At home COVID-19 antigen test kit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Self COVID-19 Antigen Home Test
Description: At home COVID-19 antigen test kit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care COVID-19 Test
Description: Standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care COVID-19 Test
Description: Standard of care

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR Test
Description: High Sensitivity RT-PCR COVID-19 Test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR Test
Description: High Sensitivity RT-PCR COVID-19 Test
Study: NCT05696717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampreloxetine
Description: Oral tablet, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ampreloxetine
Description: Oral tablet, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampreloxetine
Description: Oral tablet, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, QD
Study: NCT05548114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gastrojejunostomy
Description: AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
Study: NCT06186739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based motor rehabilitation training participated by caregivers
Description: The knowledge provider was a multi-disciplinary home-based rehabilitation nursing team, which is composed of advanced practice nurse (APN) who engaged in professional rehabilitation of stroke, neurologists, rehabilitation doctors and physical therapists. Among them, APN mainly carry out and supervise family rehabilitation education and all members are collectively responsible for the adjustment and optimization of the program content. After the assessment is completed, the patient's current functional status will be confirmed. based on this, team members recommend home-exercise items that match the patient's motor function state . In this intervention programme, the content of the intervention was developed based on the recommendations of internationally published guidelines related to the rehabilitation of ischemic patients, with some adjustments to consider the cultural appropriateness of implementation in China.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine self-care
Description: the patients in this group will be routinely given post-discharge health education, such as secondary prevention measures, education on medication adherence, universal guidance on the content of home care, universal rehabilitation-related education such as correct limb positioning, post-discharge precautions, and medical referral-related assistance.
Study: NCT05831917

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: All patients were treated with Unity MRI Linac intensity modulated radiation therapy, daily imaging of MRI-IGRT and online target delineation, redesign, and total radiation dose: GTV 70Gy/33f, GTVLN 70Gy/33f, CTV 60Gy/33f, CTVLN 54Gy/33f, 5 days per week. Dose limit: The average dose to the upper, middle, and lower pharyngeal constrictor muscles is ≤ 40-50Gy, with oropharyngeal cancer requiring an average dose to the upper, middle, and lower pharyngeal constrictor muscles to be ≤ 50Gy and ≤ 20Gy; Lower pharyngeal cancer requires an average dose of ≤ 40Gy for the upper and middle pharyngeal constrictor muscles, and ≤ 50Gy for the lower pharyngeal constrictor muscles.~chemotherapy: cisplatin 75mg/m2, 21 days per cycle, a total of 3 cycles.
Study: NCT05548114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical gastrojejunostomy
Description: A surgical gastrojejunostomy will be created via laparoscopic (preferred) or open technique, as clinically appropriate.
Study: NCT05488340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01 0.1 x IV dose
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01 0.01x IV Dose
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01 IV Infusion Dose
Description: Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose regimen selected from Part 1 of placebo (Tris buffer).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01
Description: Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP/SMX
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP/SMX
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP/SMX
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP/SMX
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMP/SMX
Description: TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
Study: NCT05268276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-perineal ice-gel pad application
Description: For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-performance of pelvic floor exercises (Kegel exercises)
Description: women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3- perineal warm compresses application
Description: women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
Study: NCT06274632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADELANTE
Description: A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
Study: NCT05004415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 (R07496998)
Description: Study participants will receive a single radiolabeled dose of 550 mg AT-527.
Study: NCT06453577

Intervention type: DRUG
Intervention: Recompensation (guideline directed medical therapy)
Description: Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.
Study: NCT06387342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namodenoson 25mg
Description: oral capsule
Study: NCT04915599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooral® mouth cooling device (MCD)
Description: Cooral® mouth cooling device (MCD) to prevent oral mucositis (QM) in patients undergoing radiation therapy for head and neck malignancies
Study: NCT04680741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction Pilot App behavior tracking
Description: a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.
Study: NCT06319664

Intervention type: PROCEDURE
Intervention: retrosigmoid approach (RSA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: retrosigmoid approach (RSA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: retrosigmoid approach (RSA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: subtemporal transtentorial transpetrosal approach (STTA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: extended pterional transtentorial approach (EPTA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: pretemporal trancavernous anterior transpetrosal approach (PTCA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: presigmoid combined supra-infratentorial approach (PCA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: presigmoid combined supra-infratentorial approach (PCA)
Description: The skull base approach choice was fundamentally followed by the modified classification.

Intervention type: PROCEDURE
Intervention: inoperable
Description: The skull base approach choice was fundamentally followed by the modified classification.
Study: NCT04731051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ01
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care (SOC) for COVID-19
Description: Standard of care (SOC) for COVID-19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care (SOC) for COVID-19
Description: Standard of care (SOC) for COVID-19